Precision BioSciences Inc. (DTIL) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Precision BioSciences Inc. (NASDAQ: DTIL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $7.06 (-5.11% 1D, market cap $205.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DTIL ranks #954 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DTIL carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ARTV (Artiva Biotherapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $206.8M) and PALI (Palisade Bio Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $207.4M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
Per DTIL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001357874), Precision BioSciences Inc. generated $34.3M in revenue (-50.1% YoY), -$45.7M in net income, and -$65.8M in free cash flow against $154.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 58% of 52W Range • RSI-14 at 55.8 (BULLISH MOMENTUM)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While DTIL currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.90) and Max Pain ($7.41) forces dealer call-delta covering toward $10.10.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Precision BioSciences Inc. (DTIL) dropped -5.11% to $7.06, trading at 58% of its 52-week range ($3.53 – $9.62). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
DURHAM, N.C., October 29, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet n
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -50.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DTIL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DTIL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Precision BioSciences Inc. (DTIL) ranks #954 by composite RQD confidence (24/100, grade E) and #574 by equity capitalization ($205.4M). Within this direct 5-issuer industry benchmark cohort, CGEN leads on earnings valuation at 5.5x trailing P/E, while CGEN leads on capital efficiency and profitability with 85.0% ROIC and 87.3% gross margin. CGEN currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with DTIL at 24/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DTIL
ACTIVE
Precision BioSciences Inc. | E | 24/100 | — | — | -35.0% | -5.11% | $205.4M | Benchmark Subject |
| ARTV Artiva Biotherapeutics Inc. | D- | 39/100 | — | — | -35.0% | -0.95% | $206.8M | /artv-vs-dtil → |
| PALI Palisade Bio Inc. | D- | 43/100 | — | — | -35.0% | -2.52% | $207.4M | /pali-vs-dtil → |
| PLX Protalix BioTherapeutics Inc. | E | 28/100 | — | 48.8% | -13.0% | -0.77% | $210.3M | /plx-vs-dtil → |
| CGEN Compugen Ltd. | B+ | 78/100 | 5.5x | 87.3% | 85.0% | -2.94% | $193.0M | /cgen-vs-dtil → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Precision BioSciences Inc. (DTIL) reported GAAP revenue of $34.3M (-50.1% vs. FY2024 revenue of $68.7M , and -29.7% cumulative change since FY2023) , GAAP net income of -$45.7M, operating cash flow of -$65.8M, and free cash flow of -$65.8M (-12.7% YoY). On the balance sheet, DTIL closed FY2025 with $154.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $34.3M | -$45.7M | -$65.8M | -$65.8M | $154.4M | — |
| FY2024 (FY) | 2024-12-31 | $68.7M | $7.2M | -$58.4M | -$58.4M | $136.4M | — |
| FY2023 (FY) | 2023-12-31 | $48.7M | -$61.3M | -$84.1M | -$84.1M | — | — |
As of 2026-11-02, Precision BioSciences Inc. (NASDAQ: DTIL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $7.06 (-5.11% 1D, market cap $205.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DTIL ranks #954 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DTIL carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ARTV (Artiva Biotherapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $206.8M) and PALI (Palisade Bio Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $207.4M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
Per DTIL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001357874), Precision BioSciences Inc. generated $34.3M in revenue (-50.1% YoY), -$45.7M in net income, and -$65.8M in free cash flow against $154.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
DTIL last traded at $7.06 (-5.11% on volume of 108,937 shares), positioning the stock +2.32% above its 50-day simple moving average ($6.90) and +7.95% above its 200-day simple moving average ($6.54). Across its 52-week range of $3.53 to $9.62, DTIL sits at the 58.0% percentile with a 14-day RSI of 55.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($6.18 to $7.94).
Why DTIL Stock dropped -5.11% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).